A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus
Divya Koura(University of California San Diego), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Joseph Maroge(University of California San Diego), James Mirocha(Cedars-Sinai Medical Center), Carolyn Mulroney(University of California San Diego Medical Center), Ah‐Reum Jeong(University of California San Diego), Kaitlyn C. Dykes(University of California San Diego), Caitlin Costello(University of California San Diego), Michelle Padilla(University of California San Diego), Aaron M. Goodman(University of California San Diego), Edward D. Ball(Sheba Medical Center), Tiffany Tanaka(UC San Diego Health System), Ayad Hamdan(University of California San Diego), James K. Mangan(UC San Diego Health System)
Cited by 1
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|601
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
|Nature Reviews Clinical Oncology|2016|464